Videos

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD

Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses the efficacy of alectinib after first-line crizotinib in patients with ALK-positive lung cancer. Baik says alectinib generally works for about 8 months and is easy to take for patients.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma.

Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the future of immunotherapies and anti-HER2 drugs in the treatment paradigm for HER2-positive breast cancer.

Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer.

Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC).

Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC).

Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses the pros and cons of multi-gene assays when trying to determine the risk of local recurrence in patients with breast cancer.

Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy.

Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.

​Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer.

Hays says current genetic testing gives oncologists a wide variety of information that may make choosing the correct treatment "a little more difficult." Hays adds that within the current treatment paradigm of gynecologic cancer, oncologists are mainly focusing on BRCA mutations.

Partridge says that the current school of thought is younger women should be treated the same as older women with breast cancer, though younger women tend to develop more aggressive breast cancer with more nodal involvement.

Perou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.

Cooperberg says a growing body of evidence dictates that surgery in prostate cancer may be a more effective local therapy than radiation alone.

Boughey says an ongoing national clinical trial is looking at patients with ER+ breast cancer and treating them with neoadjuvant endocrine therapy.

Partridge says there continues to be a growing epidemic of women getting a bilateral mastectomy for unilateral breast cancer. These surgeries include women who are not at high-risk.

Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Atkins says because treatments currently used in patients with visible metastatic melanoma are normally efficacious between 50% and 60% of the time, then the expectation for these treatments in the adjuvant setting could be effective around 80% of the time.